beta-Casomorphin-7 (BCM-7)

beta-Casomorphin-7 (BCM-7) is a seven-amino acid exogenous opioid peptide (Tyr-Pro-Phe-Pro-Gly-Pro-Ile) derived from the proteolytic digestion of the A1 variant of bovine beta-casein [1, 4]. It acts primarily as a potent agonist of the mu-opioid receptor (MOR) located in the gastrointestinal tract and central nervous system, influencing gut motility, mucus secretion, and inflammatory responses [7, 10]. The formation of BCM-7 is attributed to a specific genetic mutation in A1 beta-casein that replaces proline with histidine at position 67, making the peptide chain vulnerable to enzymatic cleavage [6, 12]. Clinically, BCM-7 has been linked to gastrointestinal discomfort and controversially associated with non-communicable conditions such as type 1 diabetes, autism, and atopic dermatitis [2, 9, 14]. Its biological activity can be antagonized by opioid blockers like naloxone, and its levels are naturally regulated by the degrading enzyme dipeptidyl peptidase IV (DPP-4) [9, 15]. As it is an exogenous ligand rather than a therapeutic target protein, BCM-7 is mostly discussed in the context of nutritional science and its potential role in disease pathogenesis [7, 13].

Other names

BCM-7BCM7beta-casomorphin 7bovine beta-casomorphin-7beta-casein fragment (60-66)

Agonism of the mu-opioid receptor (MOR); Potential inhibition of 5-HT2 serotonin receptors; Stimulation of histamine release from mast cells